Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
- Author
- ZEMEK, Filip1 ; DRTINOVA, Lucie2 ; NEPOVIMOVA, Eugenie1 3 ; SEPSOVA, Vendula1 ; KORABECNY, Jan1 3 ; KLIMES, Jiri4 5 ; KUCA, Kamil6
[1] University of Defence, Department of Toxicology, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic
[2] University of Defence, Centre of Advanced Studies, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic
[3] University Hospital, Biomedical Research Centre, Hradec Kralove, Czech Republic
[4] Charles University in Prague, Faculty of Pharmacy Hradec Kralove, Department of Clinical and Social Pharmacy, Czech Republic
[5] Institute of Health Economics and Technology Assessment, o.p.s, iHETA, Prague, Switzerland
[6] University Hospital, Biomedical Research Centre, Hradec Kralove, Sokolska 801, Hradec Kralove 500 01, Czech Republic - Source
Expert opinion on drug safety. 2014, Vol 13, Num 6, pp 759-774, 16 p ; ref : 105 ref
- ISSN
- 1474-0338
- Scientific domain
- Pharmacology drugs; Toxicology
- Publisher
- Informa, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Alzheimer's diseases acetylcholinesterase donepezil galantamine memantine rivastigmine
- Keyword (fr)
- Acetylcholinesterase Antialzheimer Anticholinestérasique Antiparkinsonien Article synthèse Donépézil Démence d'Alzheimer Galantamine Mémantine Nootrope Pronostic Psychotrope Revue bibliographique Rivastigmine Toxicité Traitement Benzofurobenzoazépine dérivé Alcaloïde Antagoniste Carboxylic ester hydrolases Dérivé de l'amantadine Dérivé de la benzoazépine Dérivé de la pipéridine Enzyme Esterases Hydrolases Inhibiteur enzyme Maladie dégénérative Parasympathomimétique Pathologie de l'encéphale Pathologie du système nerveux central Pathologie du système nerveux Récepteur NMDA Récepteur glutamate
- Keyword (en)
- Acetylcholinesterase Antialzheimer agent Anticholinesterase agent Antiparkinson agent Review Donepezil Alzheimer disease Galantamine Memantine Nootropic agent Prognosis Psychotropic Bibliographic review Rivastigmine Toxicity Treatment Alkaloid Antagonist Carboxylic ester hydrolases Amantadine derivatives Benzazepine derivatives Piperidine derivatives Enzyme Esterases Hydrolases Enzyme inhibitor Degenerative disease Parasympathomimetic Cerebral disorder Central nervous system disease Nervous system diseases NMDA receptor Glutamate receptor
- Keyword (es)
- Acetylcholinesterase Antialzheimer Anticolinesterasa agente Antiparkinsoniano Artículo síntesis Donepezilo Demencia Alzheimer Galantamina Memantina Nootropo Pronóstico Psicotropo Revista bibliográfica Rivastigmina Toxicidad Tratamiento Alcaloide Antagonista Carboxylic ester hydrolases Amantadina derivada Benzoazepina derivado Piperidina derivado Enzima Esterases Hydrolases Inhibidor enzima Enfermedad degenerativa Parasimpatomimético Encéfalo patología Sistema nervosio central patología Sistema nervioso patología Receptor NMDA Receptor glutámato
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02U Drug toxicity and drugs side effects treatment
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B18 Psychopathology. Psychiatry / 002B18C Adult and adolescent clinical studies / 002B18C13 Organic mental disorders. Neuropsychology
- Francis
- 770 Psychology. Psychoanalysis. Psychiatry / 770-D Psychopathology. Psychiatry / 770-D03 Adult and adolescent clinical studies / 770-D03M Organic mental disorders. Neuropsychology
- Discipline
- Drugs toxicity and drug intoxications Neurology Psychopathology. Psychiatry. Clinical psychology Toxicology
- Origin
- Inist-CNRS
- Database
- FRANCIS ; PASCAL
- INIST identifier
- 28596200
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Expert opinion on drug safety\";s:9:\"\u0000*\u0000stitle\";s:21:\"Expert opin. drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"759\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1474-0338\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ZEMEK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Filip\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:15:\"DRTINOVA, Lucie\";i:1;s:19:\"NEPOVIMOVA, Eugenie\";i:2;s:16:\"SEPSOVA, Vendula\";i:3;s:14:\"KORABECNY, Jan\";i:4;s:12:\"KLIMES, Jiri\";i:5;s:11:\"KUCA, Kamil\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Expert opinion on drug safety\";s:9:\"\u0000*\u0000stitle\";s:21:\"Expert opin. drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"759\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1474-0338\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ZEMEK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Filip\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:15:\"DRTINOVA, Lucie\";i:1;s:19:\"NEPOVIMOVA, Eugenie\";i:2;s:16:\"SEPSOVA, Vendula\";i:3;s:14:\"KORABECNY, Jan\";i:4;s:12:\"KLIMES, Jiri\";i:5;s:11:\"KUCA, Kamil\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Expert opinion on drug safety\";s:9:\"\u0000*\u0000stitle\";s:21:\"Expert opin. drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"759\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1474-0338\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ZEMEK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Filip\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:15:\"DRTINOVA, Lucie\";i:1;s:19:\"NEPOVIMOVA, Eugenie\";i:2;s:16:\"SEPSOVA, Vendula\";i:3;s:14:\"KORABECNY, Jan\";i:4;s:12:\"KLIMES, Jiri\";i:5;s:11:\"KUCA, Kamil\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Expert opinion on drug safety\";s:9:\"\u0000*\u0000stitle\";s:21:\"Expert opin. drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"759\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1474-0338\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ZEMEK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Filip\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:15:\"DRTINOVA, Lucie\";i:1;s:19:\"NEPOVIMOVA, Eugenie\";i:2;s:16:\"SEPSOVA, Vendula\";i:3;s:14:\"KORABECNY, Jan\";i:4;s:12:\"KLIMES, Jiri\";i:5;s:11:\"KUCA, Kamil\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Expert opinion on drug safety\";s:9:\"\u0000*\u0000stitle\";s:21:\"Expert opin. drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"759\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1474-0338\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ZEMEK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Filip\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:15:\"DRTINOVA, Lucie\";i:1;s:19:\"NEPOVIMOVA, Eugenie\";i:2;s:16:\"SEPSOVA, Vendula\";i:3;s:14:\"KORABECNY, Jan\";i:4;s:12:\"KLIMES, Jiri\";i:5;s:11:\"KUCA, Kamil\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
